Hanan Alameddin

Dr. Hanan Alameddin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LZLori Zarmer
Lori Zarmer
MKMaaz Shah Khan
Maaz Shah Khan
GIGlenn Islat
Glenn Islat
HAHanan Alameddin
Hanan Alameddin
MMMaria A Massey
Maria A Massey
RCRabail Arif Chaudhry
Rabail Arif Chaudhry
Traumatic spinal cord injury (tSCI) is a devastating neurological disorder with profound effects on physical, psychological, and mental abilities. tSCI affects all age groups, with a higher incidence in elderly patients. There are many causes of tSCI, with motor vehicle accidents (MVA) and falls being the most common. The pathophysiology of tSCI is quite complex and involves primary and secondary injury. The primary injury directly results from the mechanical forces that caused the injury. Secondary injury is caused by long-term changes caused by inflammation, immune changes, and the formation of free radicals. Numerous studies have explored various medical and surgical treatment options that help mitigate long-term damage caused by tSCI and help improve quality of life. Currently, there are no treatments for tSCI that can reverse spinal cord damage or fully restore motor and sensory functions. However, many pharmacological and non-pharmacological options are being studied in tSCI patients. This review will discuss the background, pathophysiology, and clinical presentation of tSCI while also providing a detailed analysis of the recent advancements in treatment options.

10 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LZLori Zarmer
Lori Zarmer
MKMaaz Shah Khan
Maaz Shah Khan
GIGlenn Islat
Glenn Islat
HAHanan Alameddin
Hanan Alameddin
MMMaria A Massey
Maria A Massey
RCRabail Arif Chaudhry
Rabail Arif Chaudhry
Background/Objectives: Traumatic brain injury (TBI) is a major global cause of death and disability, with long-term cognitive, behavioral, and functional consequences. Despite its high burden, management is complicated by heterogeneous presentations and limited evidence. This review summarizes recent advances in monitoring, therapeutic strategies, neuroprotection, and rehabilitation, while highlighting future directions toward individualized and globalized care. Methods: This paper is a narrative review of clinical trials, systematic reviews, and observational studies, focusing on invasive and non-invasive monitoring, pharmacologic and non-pharmacologic interventions, neuroprotective agents, stem cell therapy, and advanced rehabilitation modalities. Results/Findings: Our review focuses on emerging monitoring techniques, including brain tissue oxygenation, cerebral microdialysis, and multimodal strategies, that provide detailed insights but lack standardized application. Interventions such as anti-inflammatory agents, hypothermia, hyperosmolar therapies, and metabolic suppression show mixed efficacy, with few therapies supported by high-level evidence. Novel agents like erythropoietin and progesterone demonstrate neuroprotective potential in preclinical models but remain inconclusive in clinical trials. Stem cell therapies and extracellular vesicle approaches are promising in early studies. Rehabilitation is expanding with virtual reality, robotics, and neurostimulation to promote neuroplasticity. Personalized medicine approaches incorporating biomarkers and machine learning may refine prognostication and guide therapy. Global inequities persist, particularly in low-resource settings. Conclusions: TBI care is shifting toward individualized, multimodal, and technology-driven strategies. While emerging therapies show promise, high-quality randomized trials and global implementation strategies are needed to improve outcomes and reduce disparities.

9 March 2026 in Scientific Reports
Verified
Journal Article
Open access
HAHanan Alameddin
Hanan Alameddin
WAWafaa Alabsi
Wafaa Alabsi
BEBasanth Babu Eedara
Basanth Babu Eedara
NANeftali Ortega Alarcon
Neftali Ortega Alarcon
RARichard L De Armond
Richard L De Armond
HMHeidi M. Mansour
Heidi M. Mansour
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by the upper airway collapse, leading to interrupted breathing and reduced oxygen levels during sleep. This condition often results in chronic inflammation and is associated with various long-term health problems. To address OSA-related inflammation, an FDA-approved drug, Doxycycline, was formulated in this study as a dry powder inhaler due to its favorable anti-inflammatory properties that was tested in subsequent cellular and animal studies of OSA. This comprehensive and systematic study aimed to develop inhalable excipient-free spray-dried (SD) one-component drug powders of Doxycycline . Advanced organic solution spray-drying in closed mode, with three different feed pump rates (10%, 50%, and 100%), was used to design and produce Doxycycline microparticles in the solid state successfully. The SD Doxycycline formulations comprised hollow, spherical, dimpled particles (60% with NeoHaler inhaler device (63.19 ± 7.59 to 68.53 ± 3.73%) while HandiHaler showed lower RF (39.61± 0.57 to 53.90 ± 8.03%). The fine particle fraction (FPF) was higher in the NeoHaler group (24.91 ± 1.17 to 36.72 ± 2.01%) compared to HandiHaler (19.61 ± 5.41 to 33.76 ± 5.21%). This could be explained by the difference in median aerodynamic diameter (8.21 ± 2.68 to 4.69± 1.27 μm) in the NeoHaler group compared to (3.07 ± 0.36 to 3.67 ± 0.59 μm) HandiHaler group. Furthermore, in vitro cell viability as a function of lung cell type and drug dose showed 10 µM of Doxycycline as a safe concentration for the A549, H358, H441, and Calu-3 epithelial-like immortal human cell lines. Inhalable dry powder formulation of Doxycycline could offer new treatment options for patients suffering from sleep apnea.